AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33600437
Drug: Intraplexus injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraplexus injection of 25mL ropivacaine 0.5% between C5‐C6 nerve roots
Trial: 33600437
Drug: Extraplexus injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraplexus injection of 25mL ropivacaine 0.5% anterior and posterior to the brachial plexus
Trial: 33243209
Drug: Melatonin 1
RxNorm normalized name: melatonin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 1 mg/morning and 3 mg/at bedtime (Group IIIb)
Trial: 36036539
Drug: Efgartigimod (FcRn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efgartigimod (FcRn antagonist)
Trial: 36483622
Drug: Ticagrelor loading
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor loading dose (LD)
Trial: 33029267
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml methylene blue
Trial: 33029267
Drug: 3.5 ml
RxNorm normalized name: ethanol 3.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 ml methylene blue
Trial: 33029267
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml methylene blue
Trial: 33029267
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml methylene blue
Trial: 35568804
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy with clopidogrel plus aspirin
Trial: 33551196
Drug: Dasatinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (150 mg orally daily for 14 days), followed by paclitaxel, carboplatin and dasatinib (daily) for six cycles (21-day cycles)
Trial: 32175587
Drug: Survey responders
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Survey responders in the intervention group who previously reported non-vaccine use
Trial: 34210347
Drug: Combined tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined tDCS and VR-based therapy (30 minutes each)
Trial: 34210347
Drug: Combined tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined tDCS and VR-based therapy
Trial: 36190145
Drug: Two short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two short implants (6 mm) with single-unit restorations (group TWO)
Trial: 36190145
Drug: One single
RxNorm normalized name: Risperidone Single-Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single short implant (6 mm) with a cantilever restoration (group ONE-C)
Trial: 36190145
Drug: Implants that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants that survived
Trial: 32112126
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia and a continuous intraarticular catheter with ropivacaine (group L)
Trial: 32474816
Drug: Adjuvant capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant capecitabine chemotherapy
Trial: 35858154
Drug: Oral Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Paclitaxel plus Encequidar (oPac + E) 205 mg/m2 paclitaxel plus 15 mg E, 3 consecutive days per week
Trial: 35858154
Drug: Intravenous Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous Paclitaxel (IVpac) 175 mg/m2 once every 3 weeks
Trial: 35858154
Drug: Oral Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Paclitaxel plus Encequidar (oPac + E)
Trial: 35858154
Drug: Intravenous Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous Paclitaxel (IVpac)
Trial: 32959110
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of ASA administered in the evening (n = 56)
Trial: 32959110
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of ASA administered in the morning (n = 58)
Trial: 36038163
Drug: Lobe-specific lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobe-specific lymph node dissection (L-SLND)
Trial: 34964825
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection (US)
Trial: 34964825
Drug: Freehand injection
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Freehand injection (FH)
Trial: 32649717
Drug: Intravenous hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydromorphone (IVH)
Trial: 35564858
Drug: Control (activities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (activities of daily living)
Trial: 32700798
Drug: S-Praziquantel (S-PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-Praziquantel (S-PZQ) with ketoconazole (KTZ) as a CYP3A inhibitor
Trial: 32700798
Drug: R-Praziquantel (R-PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: R-Praziquantel (R-PZQ) with ketoconazole (KTZ) as a CYP3A inhibitor
Trial: 35412448
Drug: Interocclusal splint
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interocclusal splint therapy, diclofenac, and TMJ mobilization
Trial: 32568867
Drug: Entecavir monotherapy
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir monotherapy (n = 70)
Trial: 32568867
Drug: Entecavir add-on
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir add-on peg-interferon therapy (n = 74)
Trial: 32568867
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (monotherapy and combination therapy)
Trial: 35804307
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (cisplatin and 5-fluorouracil plus radiotherapy followed by surgical resection)
Trial: 35804307
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (cisplatin, 5-fluorouracil, and epirubicin chemotherapy with concurrent extended volume radiotherapy following surgical resection)
Trial: 34916645
Drug: Non-surgical peri-implantitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical peri-implantitis treatment combined with systemic antimicrobials
Trial: 34916645
Drug: Full mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full mouth non-surgical peri-implantitis treatment
Trial: 35560305
Drug: High Sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Sodium (HS) diet (6,900 mg/day) with Placebo (PL)
Trial: 35560305
Drug: High Sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Sodium (HS) diet (6,900 mg/day) with Antioxidants (AO)
Trial: 35560305
Drug: Low Sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Sodium (LS) diet (2,300 mg/day) with Placebo (PL)
Trial: 35560305
Drug: Low Sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Sodium (LS) diet (2,300 mg/day) with Antioxidants (AO)
Trial: 34438029
Drug: SZL (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SZL (3.2 g/d)
Trial: 34438029
Drug: FLX (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLX (20 mg/d)
Trial: 34918639
Drug: Bismuth potassium
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth potassium citrate capsules (220 mg)
Trial: 34918639
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth pectin capsules (200 mg)
Trial: 34918639
Drug: Bismuth pectin
RxNorm normalized name: bismuth / pectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth pectin granules (150 mg)
Trial: 34918639
Drug: Bismuth pectin
RxNorm normalized name: bismuth / pectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth pectin granules (300 mg)
Trial: 32563609
Drug: Low-dosage sIPV
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage sIPV
Trial: 32563609
Drug: Medium-dosage sIPV
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dosage sIPV
Trial: 32563609
Drug: High-dosage sIPV
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage sIPV
Trial: 33414503
Drug: CPAP (Continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP (Continuous Positive Airway Pressure) treatment
Trial: 32370818
Drug: escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram 10 mg/tab daily
Trial: 32370818
Drug: moclobemide 150
RxNorm normalized name: moclobemide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide 150 mg/tab daily
Trial: 32316129
Drug: Passiflora setacea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passiflora setacea juice (250 mL)
Trial: 36241898
Drug: Low-volume high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume high-intensity interval training (HIIT), 12 weeks, 3 times weekly on a rowing ergometer, average power output of 138 W
Trial: 32807632
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) with aerobic exercise plus usual care (UC)
Trial: 32095843
Drug: Prilocaine +
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prilocaine + Tramadol 1 mg/kg (P + T1)
Trial: 32095843
Drug: Prilocaine +
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prilocaine + Tramadol 2 mg/kg (P + T2)
Trial: 32095843
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (Control group)
Trial: 34554649
Drug: Home-based aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based aerobic exercise at 40-60% peak heart rate thrice weekly and resistance training at 70% of one-repetition maximum twice weekly for 6 months
Trial: 36138535
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of TXA (2 g bolus within 45 minutes of injury)
Trial: 36138535
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of TXA (1 g bolus plus 1 g 8 h infusion after 45 minutes of injury)
Trial: 32457012
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg intravenous)
Trial: 36231604
Drug: Neurorehabilitation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurorehabilitation treatment plus ultrasound-guided dry needling
Trial: 36231604
Drug: Neurorehabilitation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurorehabilitation treatment
Trial: 33961812
Drug: Sit-to-stand exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sit-to-stand exercises and protein-rich nutritional supplements (12-week intervention)
Trial: 33961812
Drug: Sit-to-stand exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sit-to-stand exercises and protein-rich nutritional supplements
Trial: 32460618
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) therapy using low energy, nonionizing light primarily in the visible or near-infrared spectrum.
Trial: 32205155
Drug: Normothermia and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermia and early treatment of fever (≥37.8 °C)
Trial: 35180099
Drug: Graston Technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graston Technique (GT) combined with Conventional Physical Therapy (CPT)
Trial: 35419831
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with S‐1 (CCRT)
Trial: 32139204
Drug: IV chlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV chlorpheniramine (CPM), IV dexamethasone (CPM/Dex), and oral prednisolone for 5 days (CPM/Dex/Pred)
Trial: 36281627
Drug: Mexiletine (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (333 mg oral dose)
Trial: 33248918
Drug: Intraarterial BMSC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial BMSC injection (group B)
Trial: 33248918
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (group A)
Trial: 36456477
Drug: Cervical injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical injection group (1 ml of nano-carbon injected at 3 and 9 o'clock in the cervix)
Trial: 36456477
Drug: Uterine injection
RxNorm normalized name: ETHIODIZED OIL 480 mg in 1 mL INTRAUTERINE INJECTION [LIPIODOL]
DrugBank: Methylergometrine (DB00353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uterine injection group (4 ml of methylene blue injected into the uterine body at 2 sites)
Trial: 36456477
Drug: Combined injection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined injection group (1 ml of nano-carbon + 4 ml of methylene blue)
Trial: 32682370
Drug: Tremelimumab (anti-CTLA-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (anti-CTLA-4 antibody)
Trial: 34709010
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose 1 µg/kg and maintenance dose 0.25 µg/kg/h)
Trial: 34709010
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose 1 µg/kg and maintenance dose 0.5 µg/kg/h)
Trial: 33106028
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (single injection, with or without ultrasound guidance)
Trial: 33106028
Drug: Second corticosteroid
RxNorm normalized name: 60 Second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second corticosteroid injection
Trial: 33106028
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (across all groups)
Trial: 36317442
Drug: Quercetin 500
RxNorm normalized name: quercetin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 500 mg daily for 40 days
Trial: 32046865
Drug: Serum PTH
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PTH levels < 2.9 pmol/L measured 1 hour after surgery and on the first postoperative day
Trial: 32046865
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of calcium supplements
Trial: 36235798
Drug: Psyllium (fiber‐matched,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (fiber‐matched, 7.5 g/day)
Trial: 32736141
Drug: Control (C)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (C) rinsing with saline solution for 90 seconds
Trial: 34580096
Drug: Temocillin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocillin (2 g three times a day)
Trial: 34580096
Drug: Carbapenem (meropenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbapenem (meropenem 1 g three times a day or ertapenem 1 g once daily)
Trial: 32747013
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus sorafenib (bevacizumab 5 mg/kg IV every 2 weeks, sorafenib 200 mg bid 5 days-on/2 days-off)
Trial: 34655547
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol eye drops administered twice daily
Trial: 32210440
Drug: TGF‐?RI/ALK5 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF‐?RI/ALK5 inhibitor galunisertib
Trial: 36059921
Drug: Promethazine 12.5
RxNorm normalized name: promethazine 12.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine 12.5 mg and dexamethasone 8 mg
Trial: 32941872
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy for 23 months after 1 month of ticagrelor combined with aspirin
Trial: 36999409
Drug: Standard dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dual antiplatelet therapy (DAPT) for 12 months
Trial: 32584909
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) model for predicting obstructive CAD
Trial: 32584909
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) model for revascularization
Trial: 32584909
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of imaging variables from ML model
Trial: 35785559
Drug: Needle acupuncture
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle acupuncture (10-week bilateral treatment of ST34, EX–LE12, and EX–LE8)
Trial: 34373044
Drug: safinamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safinamide (50 mg/day) for 3 months
Trial: 35229713
Drug: Personalised hip
RxNorm normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised hip therapy (individualised physiotherapist-led programme of conservative care)
Trial: 33682457
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein intake (∼1.0 g·kg‐1·day‐1) during resistance training
Trial: 33682457
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein intake (∼1.6 g·kg‐1·day‐1) during resistance training
Trial: 32658754
Drug: National protocol:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: National protocol: initial dose of 100 ml followed by 100 ml 6th hourly until 20WBCT was negative or 300 ml of ASV was given, whichever was earlier
Trial: 32658754
Drug: Current protocol:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current protocol: 70 ml followed by 30 ml every 6th hourly until two consecutive 20WBCT were negative
Trial: 32658754
Drug: National ASV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: National ASV dosing protocol
Trial: 32975705
Drug: Gels containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gels containing 400 μM EGCG, 0.012% chlorhexidine, 1 mM FeSO4, 1.23% F (NaF)
Trial: 32516291
Drug: Gliclazide 30
RxNorm normalized name: gliclazide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide 30 mg/day
Trial: 32012166
Drug: Reciprocating single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reciprocating single file followed by matching-taper single-cone filling
Trial: 33151847
Drug: Immersive 360°
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive 360° video viewed through tablets
Trial: 36209081
Drug: higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: higher dose of nabiximols
Trial: 33390421
Drug: Intensive exercise
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive exercise plus 5 mg (up to 10 mg) of dapagliflozin daily (IT group)
Trial: 35147302
Drug: 3.6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g/day n‐3‐PUFA
Trial: 33675013
Drug: Home-based strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based strength exercise (twice weekly for 10 weeks) with educational materials, exercise equipment (dumbbells, resistance bands), and video coaching support.